health π Qdenga paving the way for dengue vaccine access
Three dengue vaccines have received global regulatory approval, including Qdenga, Dengvaxia, and Butantan-DV. Takeda's Qdenga got approval in India on July 2026 from CDSCO, targeting ages 4β60. Clinical data shows Qdenga has 80.2% efficacy against dengue and 90.4% against hospitalization. Vaccination can potentially affect diagnostic tests like RT-PCR shortly after administration. The future market will integrate vaccination, diagnostics, and surveillance efforts. π